Rebecca Coll

Dr Rebecca Coll is a Lecturer at Queen's University Belfast (QUB), affiliated with the School of Medicine, Dentistry and Biomedical Sciences and the Wellcome Wolfson Institute for Experimental Medicine. Her research focuses on understanding inflammasome mechanisms, particularly the NLRP3 inflammasome, and their role in inflammation, autoimmune diseases, and drug discovery. She has led projects such as 'Investigating the Thermal Biology of Inflammasomes' (2021–present) and contributed as Co-Investigator to initiatives like the Chemoproteomics Centre of Excellence (2023–present) and mass spectrometry proteomic capabilities at QUB (2023–present).

Her work aligns with UN Sustainable Development Goals, contributing to advancements in health and well-being. She has been actively involved in academic activities, including invited talks at conferences like the World Congress on Inflammation (2019), the Greater Manchester Immunology Group seminar series (2019), and the Lorne Infection and Immunity Conference (2019).

Coll's research interests emphasize the physiological and pathological roles of NLRP3 inflammasome activation, therapeutic targeting of inflammasomes, and the interplay between inflammation and metabolic disorders. Her recent studies explore novel inhibitors (e.g., bispecific antibodies, indazole derivatives) and mechanisms to regulate inflammasome activity in diseases such as atherosclerosis and acute respiratory distress syndrome (ARDS).

• Key Awards:
  • Research Australia Griffith University Discovery Award (2016)
  • Young Investigator Award (2012)
  • 2021 ICIS Regeneron New Investigator Award (2021)
  • Best Science Bite at the Lorne Infection and Immunity Conference (2019)

Coll accepts PhD students and has supervised one student (details unavailable). She collaborates extensively with the Collins Lab and other institutions to advance proteomics and drug discovery tools, particularly through mass spectrometry. Her involvement in large-scale projects highlights her role in interdisciplinary research to develop therapies targeting inflammasome-driven inflammation.

Her affiliation with the Wellcome Wolfson Institute underscores her commitment to experimental medicine, while her leadership in thermal biology studies and co-investigator roles in chemoproteomics initiatives reflect her expertise in translational research.